ESR1 and breast cancer: This finding aligns with the observation that aggressive breast cancer subtypes, such as IBC, are often HER2-positive and hormone-insensitive (ER/PR-low), suggesting that MARCKS may contribute to the hormone receptor-negative phenotype observed in these tumors.